ABSTRACT
Results are submitted of employment of intraarterial superselective polychemotherapy in the treatment of malignant tumors of female genital organs in 106 patients; of these, forty individuals presented with carcinoma of the neck of the womb, 33 with tumours of the trophoblast, 18 had carcinoma of the ovaries, and 15 carcinoma of the body of the womb. A clinical analysis was done of the results obtained as were clinical-morphological correspondences (there has been studied a therapeutic pathomorphosis of the tumours) depending on the disease stage, individual schemes of polychemotherapy. The greatest benefit from the above treatment occurred in proliferative and invasive vascular mole and choriocarcinoma; patients with carcinoma of the neck and body of the womb derived less benefit, those with carcinoma of the ovaries experienced the least therapeutic effect. Intraarterial polychemotherapy permits the generative function to be preserved in trophoblast disease, the percentage of operability to be raised in carcinoma of the neck and body of the womb.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Genital Neoplasms, Female/drug therapy , Chemotherapy, Adjuvant/methods , Female , Genital Neoplasms, Female/pathology , Humans , Infusions, Intra-Arterial , Neoplasm Staging , Postoperative Care/methods , Preoperative Care/methods , Time Factors , Treatment OutcomeABSTRACT
Results of the use of polyplatillen--a preparation consisting of sodium nucleinate (deoxyribonucleic acid) and cisplatin combined in the saline balanced solution by means of the original technique--in cancer of the ovaries (198 patients), liver (62), pancreas (35), lungs (12), stomach (5) are presented. Clearly pronounced specific activity of the preparation developed is noted.
Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Digestive System Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Nucleic Acids/administration & dosage , Ovarian Neoplasms/drug therapy , Digestive System Neoplasms/mortality , Digestive System Neoplasms/pathology , Drug Combinations , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Neoplasm Staging , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Remission Induction , Time FactorsABSTRACT
Polychemotherapy supplemented by short-time artificial hyperglycemia was carried out in 54 patients with advanced ovarian cancer. For detoxication drugs were used in 27 patients and hemosorption in 27 patients. It was found that hemosorption produced a more detoxifying effect, reduces the frequency of severe complications and allows to improve long-term results.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blood Glucose/analysis , Carcinoma/therapy , Glucose/administration & dosage , Hemoperfusion , Ovarian Neoplasms/therapy , Adult , Carcinoma/blood , Combined Modality Therapy , Evaluation Studies as Topic , Female , Fluorouracil/administration & dosage , Humans , Methotrexate/administration & dosage , Middle Aged , Ovarian Neoplasms/blood , Thiotepa/administration & dosageABSTRACT
In order to clarify the influence of induced hyperglycemia upon antitumor effects of chemotherapy we studied some animal and human tumors. We observed that hyperglycemia enhances the antitumor effects of some cytostatic drugs several fold, due in part to the changes in the microphysiology induced by the hyperglycemia. Time doubling of some transplanted rat tumors and survival time of rats, rabbits and dogs bearing the transplanted and spontaneous tumors increased two to ten fold when the chemotherapy was used under hyperglycemia. Remission duration in patients with malignant brain glioma was enhanced by an average of six months; two years survival increased two-fold and the three years survival in patients with ovarian carcinoma in Stage III-IV increased two-fold; five years survival, 1.5-fold. The number of complications due to the combination of hyperglycemia and chemotherapy were not increased significantly. The problems of combination chemotherapy and hyperglycemia for oncologic patients' treatment are under discussion.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Brain Neoplasms/drug therapy , Hyperglycemia/physiopathology , Neoplasms, Experimental/drug therapy , Ovarian Neoplasms/drug therapy , Animals , Brain Neoplasms/physiopathology , Combined Modality Therapy , Dogs , Female , Glioma/drug therapy , Glioma/physiopathology , Neoplasm Staging , Neoplasms, Experimental/physiopathology , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Ovarian Neoplasms/physiopathology , Rabbits , Rats , Rats, Inbred Strains , Remission Induction , Survival Rate , Thiotepa/administration & dosageABSTRACT
The paper is concerned with the results of CA-125 radioimmunoassay in 163 patients (584 tests) with benign and malignant ovarian diseases and other small pelvic diseases which were diagnosed before operation as ovarian tumors. CA-125 radioimmunoassay can be used in combination with other methods for investigation of patients with suspected ovarian cancer and for differential diagnosis of malignant ovarian tumors to distinguish them from other malignant tumors of the small pelvis. The total accuracy of the method, its sensitivity and specificity were 94.6%, 96.9 and 93.2%, respectively. CA-125 levels were considerably increased in malignant ovarian tumors irrespective of their histological structure. The investigation of CA-125 indices in the course of disease was indicative of the effectiveness of antitumor therapy.
Subject(s)
Antigens, Tumor-Associated, Carbohydrate/analysis , Ovarian Neoplasms/therapy , Adenocarcinoma/immunology , Adenocarcinoma/therapy , Adult , Combined Modality Therapy , Cystadenocarcinoma/immunology , Cystadenocarcinoma/therapy , Cystadenoma/immunology , Cystadenoma/therapy , Female , Humans , Middle Aged , Ovarian Neoplasms/immunology , Prognosis , RadioimmunoassaySubject(s)
Cisplatin/therapeutic use , Liver Neoplasms/drug therapy , Neoplasms, Experimental/drug therapy , Ovarian Neoplasms/drug therapy , Animals , Cisplatin/analogs & derivatives , Cisplatin/toxicity , Drug Evaluation , Drug Evaluation, Preclinical , Female , Humans , Liver Neoplasms/secondary , Male , Mice , Middle Aged , Neoplasm Transplantation , RatsABSTRACT
Assays of urine-polyamine levels were run in 66 patients with ovarian tumors. The levels of polyamine excretion were found to be significantly higher in cases of malignant epithelial tumors than in control. In the course of effective therapy, polyamine concentration showed a sharp increase followed by a decrease in posttreatment period. The index of therapy efficacy (Formula: see text) was in a strict correlation with the clinical status in 78% of cases. Polyamine tests should be recommended for diagnosis, evaluating the effectiveness of therapy and making prognosis.
